Navigation Links
USP transitions medication error reporting programs
Date:12/4/2008

Rockville, Md., December 4, 2008 In a decision to focus full attention and resources on its core standards-setting activities, USP will transfer its reporting programs, MEDMARX and the Medication Errors Reporting (MER) Program, to Quantros and the Institute for Safe Medication Practices (ISMP), respectively. This decision in no way signals a shift by USP away from its important patient safety efforts. Rather, USP will use data from these and other programs to enhance its standards-setting activities to promote patient safety and safe medication use. USP will take advantage of the growing number of new Patient Safety Organizations (PSO) to inform the product and practice standards established by its standards-setting body, the Council of Experts. The PSO is a designation created by the Federal Patient Safety and Quality Improvement Act of 2005 to encourage clinicians and healthcare organizations to identify, analyze, and reduce the risks and hazards associated with patient care, including errors associated with the administration and use of medications.

USP's leadership in medication error reporting and prevention has been an important part of its public health activities for several decades, with major contributions based on the work of distinguished volunteers in USP's Council of Experts using data and information from MEDMARX and the MER Program. "USP has been an incubator for groundbreaking pilot programs in the arena of medication error data collection, analysis and reporting," stated Roger L. Williams, M.D., USP's executive vice president and CEO. "These programs have reached the level of development where there is greater benefit to public health for USP to transfer core activities of these programs to our strategic partners, who will bring the programs to the next level of effectiveness and impact." USP will maintain access to the data from the two programs so it can be used in standards-setting activities of the Council of Experts and, particularly, in those Expert Committees that speak directly to practitioner interests. These and allied standards-setting activities are outlined in the USP Board of Trustees' new strategic plan (www.usp.org/aboutUSP/whereWereGoing.html).

USP began collecting medication error data through its own programs in 1991, but has been involved in analyzing such data for more than 30 years. USP found early on that information gleaned from error records added a medication safety component to its product standards and later led the way for its work in practice standards. USP also played an important role in the drafting and enactment of legislative changes such as the Patient Safety and Quality Improvement Act of 2005. USP continues its 188-year commitment to medication safety through its core mission of standards setting.

The following provides further information about USP reporting programs, medication safety standards setting and continued patient safety activities.

  • Expert Committees: USP's Safe Medication Use (SMU) and Nomenclature Expert Committees will continue their crucial work on setting standards for nomenclature, packaging, labeling and naming of medications to help ensure their safety.

  • National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP): In 1995, USP spearheaded the formation of NCC MERP. Fourteen leading national health care organizations came together for the first time to collaborate on addressing the interdisciplinary causes of medication errors and to promote the safe use of medications. USP will continue in its role as secretariat for NCC MERP and its 25 member organizations. Information about NCC MERP is at www.nccmerp.org.

  • Drug Error Finder: The Drug Error Finder database was launched by USP earlier in 2008 to provide clinicians and patients with a tool to help identify medications with look-alike/sound-alike names that are most frequently involved in the most harmful errors. USP will not add to the database going forward, but will leave it posted at www.usp.org/hqi/similarProducts/drugErrorFinderTool.html for free access in the interest of public health.

  • MEDMARX: For the past year, USP has worked closely with Quantros, a healthcare technology company recently named as a PSO, to create a more robust database of medication and other medical errors, and to deliver the output to a larger base of providers through an improved user interface. Quantros is well positioned to take over the complete MEDMARX operation, from data collection to analysis to dissemination. In the interest of public health and to assist practitioners and patients, USP will post its five years of MEDMARX data and eight annual reports on www.usp.org/hqi for free, ensuring full access to this clinically important information. All queries about MEDMARX should be addressed to Quantros (www.quantros.com).

  • Medication Errors Reporting (MER) Program: Since 1991, USP has had a strong partner in the Institute for Safe Medication Practices in creating this key reporting program, which has become a national model for healthcare professionals and patients to report medication errors on a confidential basis. ISMP will continue to use these reports to affect changes in products and practice both nationally and internationally. ISMP's PSO designation makes it the right organization to move the MER program forward. All queries about MER should be addressed to ISMP (www.ismp.org).


'/>"/>

Contact: Laura Provan
lnp@usp.org
301-816-8268
US Pharmacopeia
Source:Eurekalert

Related medicine news :

1. Transitions Optical to Provide Free Vision Screenings at the American Diabetes Associations Feria de Salud por tu Familia(TM)
2. Transitions Optical Offers Tips on How to Protect Eyes for Outdoor Sports Fans
3. GCI Successfully Transitions All Traffic to Galaxy 18 Satellite
4. AUDIO from Medialink and Transitions Optical: What You Cant See May Harm You
5. Healthcare Coalition Launches Enhanced Website Offering Tools and Materials to Improve Patient Care During Transitions of Care
6. Jan Marini Skin Research Introduces Age Intervention(R) Transitions - a New Frontier in Skin Care
7. AUDIO from Medialink and Transitions: Understanding the Dangers of UV Rays
8. Cliff Consulting, Inc. Transitions to Woman-Owned and Managed Firm With Robin Nasatirs Promotion to President/Chief Operating Officer
9. Transitions Optical Promotes Healthy Sight Through a Nationwide Integrated Advertising Campaign and the Launch of an Enhanced Consumer Web Site
10. New medication brings hope of jet lag cure
11. UHC and Safecor Health Announce Multi-Year Agreement for Repackaging Bar-Coded Medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView ... customers and employees that are both engaging and easy to use. Coming off ... the software company revealed today its plans to roll out new AI-powered self-service ...
(Date:12/8/2016)... ... , ... STAT courier is pleased to announce that due to customer demand, ... expanding their presence in Dallas. One of the most exciting parts for STAT is ... the Dallas and Forth Worth market. STAT takes pride in treating their employees with ...
(Date:12/8/2016)... ... 08, 2016 , ... Vida Health, the digital health platform that ... Canvas Ventures . Other investors include Nokia Growth Partners (NGP) and returning investor ... more consumers who are managing chronic conditions or simply want to improve ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... Dec. 8, 2016  EIP Pharma, LLC ( ... proof-of-mechanism for neflamapimod (previously code named VX-745), with ... clinical trials that demonstrated significant Alzheimer,s disease relevant ... treatment) and Study 303 (6-week treatment) are the ... Alzheimer,s Disease (CTAD) scientific conference in ...
(Date:12/8/2016)... A Small Business Innovative Research (SBIR) grant ... (NIH) to Phoenix -based NeuroEM Therapeutics, ... grant will seek to determine an optimal set of ... waves to treat Alzheimer,s Disease. The grant will also ... treat other neurologic disorders such as Parkinson,s Disease and ...
(Date:12/8/2016)... New York , December 8, 2016 ... global Diabetes Injection Pens Market is expected to ... compared to US$4.9 bn in 2015. Between the forecast years ... rise at a CAGR of 7.9%. The leading players operating ... A/S, Eli Lilly and Company, AstraZaneca plc., Biocon Ltd., and ...
Breaking Medicine Technology: